The FDA granted regular approval to the combination of pembrolizumab and lenvatinib for certain women with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient. The approval applies to use of the agent by women whose disease progressed after systemic therapy in any setting and who are not candidates for curative surgery or radiation. The agency had granted accelerated approval to the combination for this indication in September 2019. Continued approval was contingent upon verification and description of clinical benefit. The FDA based the
Denial of responsibility! TheTopMag.com is an automatic aggregator of all media around the world. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 72 hours.